The expanded biology of serotonin

Annual Review of Medicine

Volumn 60, Issue , 2009, Pages 355-366

  Berger, Miles ^a   Gray, John A ^a   Roth, Bryan L ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

5 HT; Behavior; Cardiovascular; Gastrointestinal; Receptor; SSRI

Indexed keywords

DULOXETINE; PAROXETINE; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE; SEROTONIN; SEROTONIN 1A RECEPTOR; SEROTONIN 1B RECEPTOR; SEROTONIN 1D RECEPTOR; SEROTONIN 2A RECEPTOR; SEROTONIN 2B RECEPTOR; SEROTONIN 2C RECEPTOR; SEROTONIN 4 RECEPTOR;

BEHAVIOR; BREATHING; CARDIOVASCULAR FUNCTION; HEART INFARCTION; HUMAN; INTESTINE MOTILITY; IRRITABLE COLON; NOCICEPTION; NONHUMAN; PREGNANCY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PULMONARY HYPERTENSION; REPRODUCTION; REVIEW; THROMBOCYTE AGGREGATION;

ANIMALS; HUMANS; SEROTONIN;

EID: 64549158645     PISSN: 00664219     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.med.60.042307.110802     Document Type: Review

References (86)

1. Rapport MM, Green AA, Page IH. 1948. Serum vasoconstrictor, serotonin; isolation and characterization. J. Biol. Chem. 176:1243-51
2. Roth BL, ed. 2007. The Serotonin Receptors: From Molecular Pharmacology to Human Therapeutics. Totowa, NJ: Humana
3. Roth BL. 1994. Multiple serotonin receptors: clinical and experimental aspects. Ann. Clin. Psychiatry 6:67-78
4. Roth BL, Xia Z. 2004. Molecular and cellular mechanisms for the polarized sorting of serotonin receptors: relevance for genesis and treatment of psychosis. Crit. Rev. Neurobiol. 16:229-36
5. Kroeze WK, Kristiansen K, Roth BL. 2002. Molecular biology of serotonin receptors: structure and function at the molecular level. Curr. Top. Med. Chem. 2:507-28
6. Kroeze WK, Hufeisen SJ, Popadak BA, et al. 2003. H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology 28:519-26
7. Roth BL. 2007. Drugs and valvular heart disease. N. Engl. J. Med. 356:6-9
8. Gershon MD, Tack J. 2007. The serotonin signaling system: from basic understanding to drug development for functional GI disorders. Gastroenterology 132:397-414
9. Mengod G, Vilaro MT, Cortes R, et al. 2007. Chemical neuroanatomy of 5-HT receptor subtypes in the mammalian brain. In The Serotonin Receptors: From Molecular Pharmacology to Human Therapeutics, ed. BL Roth, pp. 319-64. Totowa, NJ: Humana
10. Araneda R, Andrade R. 1991. 5-Hydroxytryptamine 2 and 5-hydroxytryptamine 1A receptors mediate opposing responses on membrane excitability in rat association cortex. Neuroscience 40:399-412
11. Airan RD, Meltzer LA, Roy M, et al. 2007. High-speed imaging reveals neurophysiological links to behavior in an animal model of depression. Science 317:819-23
12. Canli T, Lesch KP. 2007. Long story short: the serotonin transporter in emotion regulation and social cognition. Nat. Neurosci. 10:1103-9
13. Roth BL, Hanizavareh SM, Blum AE. 2004. Serotonin receptors represent highly favorable molecular targets for cognitive enhancement in schizophrenia and other disorders. Psychopharmacology (Berl.) 174:17-24
14. Gross C, Hen R. 2004. The developmental origins of anxiety. Nat. Rev. Neurosci. 5:545-52
15. Lesch KP. 2005. Serotonergic gene inactivation in mice: models for anxiety and aggression? Novartis Found. Symp. 268:111-40
16. Giorgetti M,Tecott LH. 2004. Contributions of 5-HT2C receptors to multiple actions of central serotonin systems. Eur. J. Pharmacol. 488:1-9
17. Gray JA, Roth BL. 2007. The pipeline and future of drug development in schizophrenia. Mol. Psychiatry 12:904-22
18. Schechter LE, Ring RH, Beyer CE, et al. 2005. Innovative approaches for the development of antidepressant drugs: current and future strategies. NeuroRx 2:590-611
19. Kaumann AJ, Levy FO. 2006. 5-hydroxytryptamine receptors in the human cardiovascular system. Pharmacol. Ther. 111:674-706
20. Hamel E. 2007. Serotonin and migraine: biology and clinical implications. Cephalalgia 27:1293-300
21. Ni W,Watts SW. 2006. 5-hydroxytryptamine in the cardiovascular system: focus on the serotonin transporter (SERT). Clin. Exp. Pharmacol. Physiol. 33:575-83
22. Carneiro AM, Cook EH, Murphy DL, Blakely RD. 2008. Interactions between integrin αIIbβ3 and the serotonin transporter regulate serotonin transport and platelet aggregation in mice and humans. J. Clin. Invest. 118:1544-52
23. Sauer WH, Berlin JA, Kimmel SE. 2003. Effect of antidepressants and their relative affinity for the serotonin transporter on the risk of myocardial infarction. Circulation 108:32-36
24. Taylor CB, Youngblood ME, Catellier D, et al. 2005. Effects of antidepressant medication on morbidity and mortality in depressed patients after myocardial infarction. Arch. Gen. Psychiatry 62:792-98
25. Glassman AH. 2005. Does treating postmyocardial infarction depression reduce medical mortality? Arch. Gen. Psychiatry 62:711-12
26. Somberg TC, Arora RR. 2008. Depression and heart disease: therapeutic implications. Cardiology 111:75-81
27. Walther DJ, Peter JU, Winter S, et al. 2003. Serotonylation of small GTPases is a signal transduction pathway that triggers platelet alpha-granule release. Cell 115:851-62
28. Dale GL. 2005. Coated-platelets: an emerging component of the procoagulant response. J. Thromb. Haemost. 3:2185-92
29. Langer C, Piper C, Vogt J, et al. 2007. Atrial fibrillation in carcinoid heart disease: the role of serotonin. A review of the literature. Clin. Res. Cardiol. 96:114-18
30. Singh S. 2004. Trials of new antiarrhythmic drugs for maintenance of sinus rhythm in patients with atrial fibrillation. J. Interv. Cardiol. Electrophysiol. 10(Suppl. 1):71-76
31. Brattelid T, Qvigstad E, Lynham JA, et al. 2004. Functional serotonin 5-HT4 receptors in porcine and human ventricular myocardium with increased 5-HT4mRNAin heart failure. Naunyn Schmiedebergs Arch. Pharmacol. 370:157-66
32. Birkeland JA, Sjaastad I, Brattelid T, et al. 2007. Effects of treatment with a 5-HT4 receptor antagonist in heart failure. Br. J. Pharmacol. 150:143-52
33. Doggrell SA. 2003. The role of 5-HT on the cardiovascular and renal systems and the clinical potential of 5-HT modulation. Expert Opin. Investig. Drugs 12:805-23
34. 2B receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications. Circulation 102:2836-41
35. Setola V, Hufeisen SJ, Grande-Allen KJ, et al. 2003. 3,4- methylenedioxymethamphetamine (MDMA, "Ecstasy") induces fenfluramine-like proliferative actions on human cardiac valvular interstitial cells in vitro. Mol. Pharmacol. 63:1223-29
36. Nebigil CG, Maroteaux L. 2003. Functional consequence of serotonin/5-HT2B receptor signaling in heart: role of mitochondria in transition between hypertrophy and heart failure? Circulation 108:902-8
37. Kereveur A, Callebert J, Humbert M, et al. 2000. High plasma serotonin levels in primary pulmonary hypertension. Effect of long-term epoprostenol (prostacyclin) therapy. Arterioscler. Thromb. Vasc. Biol. 20:2233-39
38. Esteve JM, Launay JM, Kellermann O, Maroteaux L. 2007. Functions of serotonin in hypoxic pulmonary vascular remodeling. Cell. Biochem. Biophys. 47:33-44
39. Launay JM, Herve P, Peoc'h K, et al. 2002. Function of the serotonin 5-hydroxytryptamine 2B receptor in pulmonary hypertension. Nat. Med. 8:1129-35
40. Deraet M, Manivet P, Janoshazi A, et al. 2005. The natural mutation encoding a C terminus-truncated 5-hydroxytryptamine 2B receptor is a gain of proliferative functions. Mol. Pharmacol. 67:983-91
41. Guilluy C, Rolli-Derkinderen M, Tharaux PL, et al. 2007. Transglutaminase-dependent RhoA activation and depletion by serotonin in vascular smooth muscle cells. J. Biol. Chem. 282:2918-28
42. Marcos E, Adnot S, Pham MH, et al. 2003. Serotonin transporter inhibitors protect against hypoxic pulmonary hypertension. Am. J. Respir. Crit. Care Med. 168:487-93
43. 4a receptor agonists the cure? Mol. Interv. 4:197-99
44. 4a receptors avert opioid-induced breathing depression without loss of analgesia. Science 301:226-29
45. Kinney HC, Filiano JJ, White WF. 2001. Medullary serotonergic network deficiency in the sudden infant death syndrome: review of a 15-year study of a single dataset. J. Neuropathol. Exp. Neurol. 60:228-47
46. Paterson DS,Trachtenberg FL, Thompson EG, et al. 2006. Multiple serotonergic brainstem abnormalities in sudden infant death syndrome. JAMA 296:2124-32
47. Richerson GB, Wang W, Tiwari J, Bradley SR. 2001. Chemosensitivity of serotonergic neurons in the rostral ventral medulla. Respir. Physiol. 129:175-89
48. Erickson JT, Shafer G, Rossetti MD, et al. 2007. Arrest of 5HT neuron differentiation delays respiratory maturation and impairs neonatal homeostatic responses to environmental challenges. Respir. Physiol. Neurobiol. 159:85-101
49. Tecott LH, Abdallah L. 2003. Mouse genetic approaches to feeding regulation: serotonin 5-HT2C receptor mutant mice. CNS Spectr. 8:584-88
50. Lam DD, Heisler LK. 2007. Serotonin and energy balance: molecular mechanisms and implications for type 2 diabetes. Expert Rev. Mol. Med. 9:1-24
51. Lam DD, Przydzial MJ, Ridley SH, et al. 2008. Serotonin 5-HT2C receptor agonist promotes hypophagia via downstream activation of melanocortin 4 receptors. Endocrinology 149:1323-28
52. Hodges MR, Tattersall GJ, Harris MB, et al. 2008. Defects in breathing and thermoregulation in mice with near-complete absence of central serotonin neurons. J. Neurosci. 28:2495-505
53. Hedlund PB, Kelly L, Mazur C, et al. 2004. 8-OH-DPAT acts on both 5-HT1A and 5-HT7 receptors to induce hypothermia in rodents. Eur. J. Pharmacol. 487:125-32
54. Carrasco GA, Van de Kar LD. 2003. Neuroendocrine pharmacology of stress. Eur. J. Pharmacol. 463:235-72
55. Matsuda M, Imaoka T, Vomachka AJ, et al. 2004. Serotonin regulates mammary gland development via an autocrine-paracrine loop. Dev. Cell 6:193-203
56. Stull MA, Pai V, Vomachka AJ, et al. 2007. Mammary gland homeostasis employs serotonergic regulation of epithelial tight junctions. Proc. Natl. Acad. Sci. USA 104:16708-13
57. Lesurtel M, Graf R, Aleil B, et al. 2006. Platelet-derived serotonin mediates liver regeneration. Science 312:104-7
58. Tecott LH. 2007. Serotonin and the orchestration of energy balance. Cell. Metab. 6:352-61
59. Roper SD. 2006. Cell communication in taste buds. Cell. Mol. Life Sci. 63:1494-500
60. Suzuki A, Naruse S, Kitagawa M, et al. 2001. 5-hydroxytryptamine strongly inhibits fluid secretion in guinea pig pancreatic duct cells. J. Clin. Invest. 108:749-56
61. Minami M, Endo T, Hirafuji M, et al. 2003. Pharmacological aspects of anticancer drug-induced emesis with emphasis on serotonin release and vagal nerve activity. Pharmacol. Ther. 99:149-65
62. Sommer C. 2004. Serotonin in pain and analgesia: actions in the periphery. Mol. Neurobiol. 30:117-25
63. Braz JM, Basbaum AI. 2008. Genetically expressed transneuronal tracer reveals direct and indirect serotonergic descending control circuits. J. Comp. Neurol. 507:1990-2003
64. Jann MW, Slade JH. 2007. Antidepressant agents for the treatment of chronic pain and depression. Pharmacotherapy 27:1571-87
65. Mukaida K, Shichino T, Koyanagi S, et al. 2007. Activity of the serotonergic system during isoflurane anesthesia. Anesth. Analg. 104:836-39
66. Isbister GK, Buckley NA, Whyte IM. 2007. Serotonin toxicity: a practical approach to diagnosis and treatment. Med. J. Aust. 187:361-65
67. de Jong TR, Veening JG,Waldinger MD, et al. 2006. Serotonin and the neurobiology of the ejaculatory threshold. Neurosci. Biobehav. Rev. 30:893-907
68. Giuliano F. 2007. 5-Hydroxytryptamine in premature ejaculation: opportunities for therapeutic intervention. Trends Neurosci. 30:79-84
69. Ramage AG. 2006. The role of central 5-hydroxytryptamine (5-HT, serotonin) receptors in the control of micturition. Br. J. Pharmacol. 147(Suppl. 2):S120-31
70. Basu M, Duckett J. 2008. The treatment of urinary incontinence with duloxetine. J. Obstet. Gynaecol. 28:166-69
71. Bolte AC, van Geijn HP, Dekker GA. 2001. Pathophysiology of preeclampsia and the role of serotonin. Eur. J. Obstet. Gynecol. Reprod. Biol. 95:12-21
72. Gupta S, Hanff LM, Visser W, et al. 2006. Functional reactivity of 5-HT receptors in human umbilical cord and maternal subcutaneous fat arteries after normotensive or pre-eclamptic pregnancy. J. Hypertens. 24:1345-53
73. Dawes SD. 2005. Can SSRIs reduce the risk of preeclampsia in pregnant, depressed patients? Med. Hypotheses 64:33-36
74. Salkeld E, Ferris LE, Juurlink DN. 2008. The risk of postpartum hemorrhage with selective serotonin reuptake inhibitors and other antidepressants. J. Clin. Psychopharmacol. 28:230-34
75. Chambers CD, Hernandez-Diaz S, Van Marter LJ, et al. 2006. Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. N. Engl. J. Med. 354:579-87
76. Minosyan TY, Lu R, Eghbali M, et al. 2007. Increased 5-HT contractile response in late pregnant rat myometrium is associated with a higher density of 5-HT2A receptors. J. Physiol. 581:91-97
77. Oropeza MV, Ponce Monter H, Reynoso Isla M, Campos MG. 2000. The ovarian and cervical regions of the rat uterus display a different contractile response to serotonin and prostaglandin F2á. I. The estrous cycle. Life Sci. 66:PL345-51
78. Jeffrey JJ, Ehlich LS, Roswit WT. 1991. Serotonin: an inducer of collagenase in myometrial smooth muscle cells. J. Cell Physiol. 146:399-406
79. Ruhe HG, Mason NS, Schene AH. 2007. Mood is indirectly related to serotonin, norepinephrine and dopamine levels in humans: a meta-analysis of monoamine depletion studies. Mol. Psychiatry 12:331-59
80. Weintraub M, Hasday JD, Mushlin AI, Lockwood DH. 1984. A double-blind clinical trial in weight control. Use of fenfluramine and phentermine alone and in combination. Arch. Intern. Med. 144:1143-48
81. Connolly HM, Crary JL, McGoon MD, et al. 1997. Valvular heart disease associated with fenfluraminephentermine. N. Engl. J. Med. 337:581-88
82. 2B receptors in the cardiopathy associated with fenfluramine. Mol. Pharmacol. 57:75-81
83. O'Connor KA, Roth BL. 2005. Finding new tricks for old drugs: an efficient route for public-sector drug discovery. Nat. Rev. Drug Discov. 4:1005-14
84. Droogmans S, Cosyns B, D'Haenen H, et al. 2007. Possible association between 3,4-methylenedioxymethamphetamine abuse and valvular heart disease. Am. J. Cardiol. 100:1442-45
85. Schade R, Andersohn F, Suissa S, et al. 2007. Dopamine agonists and the risk of cardiac-valve regurgitation. N. Engl. J. Med. 356:29-38
86. Zanettini R, Antonini A, Gatto G, et al. 2007. Valvular heart disease and the use of dopamine agonists for Parkinson's disease. N. Engl. J. Med. 356:39-46